



IDT AUSTRALIA LIMITED

2021 ANNUAL GENERAL MEETING

16 November 2021

Key Operational Highlights

(1 July 2020 to present)

✓ Restored IDT to Profitability

- FY`21 results reported the Company's first operating profit since 2009
- 209.6% year-on-year increase in net profit after tax, from a loss of \$1.9m in FY`20 to a profit of \$2.1m in FY`21*

✓ Sterile Manufacturing Licence Secured From The Therapeutic Goods Administration

- Finalised and successfully executed the Letter Agreement with the Australian Government, Department of Health
- IDT's cGMP sterile manufacturing facility brought into a state of readiness
- Sterile manufacturing licence secured from Therapeutic Goods Administration

✓ Delivering On IDT's Sovereign Manufacturing Initiatives

- IDT has engaged with Monash University and mRNA Victoria to manufacture the Monash Institute of Pharmaceutical Sciences (MIPS) mRNA COVID-19 receptor binding domain vaccine drug product. Australia's first locally developed mRNA COVID-19 vaccine candidate
- IDT leveraging its existing TGA and FDA accredited pharmaceutical manufacturing facilities and capabilities to assist with the supply chain challenges brought about by the COVID-19 pandemic
- The Company's submissions to the Australian Government's Approach To Market and Modern Manufacturing Initiative (Collaboration Stream) funding opportunities remain live

✓ Continuing To Execute On The Company's Medicinal Cannabis Manufacturing Plan

- Finalised process development of cannabis resin products
- Expanding stability data for flower-in-bottle and oil-in-bottle products
- Advancing a pipeline of new product development opportunities

* Including one-time adjustments (includes \$0.9 million of JobKeeper receipts)

FY`21 Year In Review*

COVID-19 Treatment and
Vaccine Manufacture – TGA and
FDA accredited site at the ready



Advance IDT's Sovereign
Manufacturing Initiative

Pushing Towards A Return To
Operational Profitability

Continue To Execute IDT's
Medicinal Cannabis
Manufacturing Plan

Finalise Development of
Proprietary Medicinal Cannabis
Products



Proprietary Medicinal Cannabis
Product Launches

Engage With Government and
Industry to Map and Better
Understand Australia's
Pharmaceutical Supply Chain

Commence Domestic
Manufacture of Essential
Medicines

* Year ahead slide presented at IDT's 2020 AGM

FY21 Financial Highlights

First Operating Profit since 2009

- Year-on-year Revenue growth of 19.5% to \$16.9 million (which includes \$0.9 million of JobKeeper receipts)
- Positive EBITDA achieved for full year 2021 which represents a year-on-year improvement of 244.9%*
- Year-on-year increase in earnings per share of 212.5%
- Strong cash balance of \$6.9 million

Year ended 30 June (\$m)	2021	2020	Variance	
Results from operations including one time adjustments*				
Revenue	16,927	14,169	2,758	↑ 19.5%
EBITDA	2,718	788	1,930	↑ 244.9%
NPAT	2,103	(1,919)	4,022	↑ 209.6%
Basic earnings per share	0.9¢	(0.8¢)	1.7¢	↑ 212.5%

Sterile Manufacturing:

Sterile Readiness Agreement Finalised

Site Licence Secured

Sterile Facility Ready To Accept Contract Development and Manufacturing Content

- Sterile Readiness Letter Agreement finalised with the Australian Government Department of Health
- IDT's flagship sterile manufacturing facility in Boronia brought into a state of sterile readiness so that IDT can use the facility to potentially provide assistance to the Government in connection with the Government's rollout of COVID-19 vaccines in Australia
- Sterile Manufacturing Licence (the Company's first ever sterile licence) secured from the Therapeutic Goods Administration
- IDT's sterile manufacturing facility is now licenced and can be deployed to support a range of sterile contract product development and manufacturing opportunities:
 - For the Australian Government, during the Letter Agreement exclusivity period; and
 - For third parties following the cessation of the Letter Agreement exclusivity period



Australian Government
Department of Health and Ageing
Therapeutic Goods Administration

Sovereign Manufacturing

COVID-19 products manufactured for Australia's National inventory

IDT manufactures Australia's first locally developed mRNA COVID-19 vaccine candidate

- Project completed for the Australian Government Department of Health at the start of the pandemic to deliver Active Pharmaceutical Ingredients and Finished Dosage Forms into Australia's National Inventory
- IDT has engaged with the Victorian Government and Monash Institute of Pharmaceutical Sciences (MIPS) to cGMP manufacture MIPS' mRNA COVID-19 receptor binding domain vaccine. This milestone will be Australia's first locally developed and manufactured mRNA drug product

Goal:

IDT's goal is to leverage its existing TGA and FDA accredited pharmaceutical manufacturing facilities and capabilities to assist with the supply chain challenges highlighted by the COVID-19 pandemic and ultimately reduce sovereign risk associated with Australia's reliance on imported medicines

mRNA Manufacturing Initiative:

IDT to become an mRNA Manufacturing Hub of Excellence

- IDT has put forward its existing licenced sterile manufacturing facility in support of a submission to the Australian Government's Onshore mRNA Manufacturing Capability: Approach To Market (ATM). ATM funding would be put towards IDT delivering a population scale end-to-end mRNA sovereign manufacturing solution
- The Company has continued to engage with industry, and has formed an alliance with Monash, Australian National University, University of Melbourne and University of Western Australia to build an mRNA ecosystem underpinning IDT's submission to the Australian Government's \$800m Modern Manufacturing Initiative Collaboration Stream grant (MMI)
- Both the ATM and the MMI opportunities are live

Goal:

IDT's goal is to expand its existing facilities and capabilities to become Australia's mRNA Manufacturing Hub of Excellence

Medicinal Cannabis

IDT continues to execute on its Medicinal Cannabis Manufacturing Plan

- Process development has been completed for IDT's medicinal cannabis resin extraction. IDT now progressing additional medicinal cannabis active pharmaceutical ingredient opportunities
- Stability programs ongoing for IDT's cGMP medicinal cannabis flower-in-bottle and oil-in-bottle products. Several of these products are now on market with more to follow
- IDT is now advancing a series of medicinal cannabis finished dosage form new product development opportunities

Goals:

IDT's goals are: (i) to provide contract development and manufacturing services to our current and future medicinal cannabis customers; and (ii) to expand our range of IDT proprietary medicinal cannabis products for local and international distribution

FY`22 Year Ahead

Demonstrate Capability With
Successful COVID-19 mRNA
Vaccine Manufacture

Strengthen IDT's
Engagement With
Government To Advance
The Company's Sovereign
Manufacturing Initiative

Progress The Business To
Sustainable Profitability

Execute On IDT's Goal To
Become an mRNA
Manufacturing Hub Of
Excellence

Continue To Execute on IDT's
Medicinal Cannabis
Manufacturing Plan


More Proprietary Medicinal
Cannabis Product Launches

Capitalise On Future
Opportunities To Build
Resilience In Australia's
Pharmaceutical Supply Chain

Build and Expand IDT's API
and Contract
Manufacturing Base
Businesses

IDT Australia Limited

Corporate Snapshot



75.5 cents

15 cents

Shares on issue	239,860,167
Options	Nil
Market Cap (as at 12 Nov 21)	\$118m
Top 20 holders	61.5% of IC
Year high	51 cents
Year low	15 cents
Cash at hand (30 Jun 21)	\$6.9m

July 2020

June 2021

IDT Australia Limited

Board of Directors

Mr Alan Fisher Chair

Experienced corporate advisor and public company director with a proven track record of implementing strategies that enhance shareholder value

Mr Hugh Burrill

Pharma pipeline portfolio management and product development
(Ex Hospira/Mayne Pharma)

Ms Mary Sontrop (Retiring)

Biopharmaceutical executive with global experience in quality, manufacturing, regulatory and business integration
(Ex CSL Behring)

Mr Michael Kotsanis

Over 30 years strategic and operational experience in the global pharmaceutical industry
(Acrux CEO, Ex Synthon, Hospira/Mayne Pharma)

Executive Team

Dr David Sparling CEO

More than 20 years of pharma and diagnostics experience in CEO, Director and Corporate/Business Development roles
(Ex Agenix Limited, GTG Limited)

Ms Ancila Desai CFO

Over fifteen years of experience in strategic finance, commercial finance, M&A, financial modelling and capital management
(Ex Metcash, Toll and Boost Juice)

Mr Jim Susic VP Operations Infrastructure

More than 20 years in manufacturing and supply chain roles
(Ex CSL Behring, Hospira/Mayne Pharma)

Mr Paul McDonald Head of Quality and Development

More than 20 years of high quality parenteral product development and manufacturing
(Ex Pfizer, Hospira)

Mr Chris Kagiros Head of People and Culture

Over 20 years in human resource roles including regional leadership positions and 14 years in pharma
(Ex CSL, Medibank and Pfizer)

Q & A

Q: How far along is the mRNA vaccine progressing?

Proxy Voting Summary

Resolution		Lodged For			Lodged Open			Lodged Against			Total Available Votes	%IC
		Votes	Holders	%	Votes	Holders	%	Votes	Holders	%		
1	Adoption of Remuneration Report	52,410,787	99	97.86%	204,299	23	0.38%	940,525	18	1.76%	53,555,611	22.33%
2	Re-election of Hugh Burrill	52,745,439	113	97.90%	338,518	22	0.63%	790,453	11	1.47%	53,874,410	22.46%

Disclaimer

This presentation is for general information purposes only and should be read in conjunction with IDT Australia Limited's Annual General Meeting on 16 November 2021.

This presentation does not provide recommendations or opinions in relation to specific investments or securities. This presentation has been prepared in good faith and with reasonable care. Neither IDT nor any other person makes any representation or warranty, express or implied, as to the accuracy, reliability, reasonableness or completeness of the contents of this presentation (including any projections, forecasts, estimates, prospects and returns), and any omissions from this presentation. To the maximum extent permitted by law, IDT and its respective directors, officers, employees and advisers disclaim and exclude all liability for any loss or damage (whether or not foreseeable) suffered or incurred by any person acting on any information (including any projections, forecasts, estimates, prospects and returns) provided in, or omitted from, this presentation or any other written or oral information provided by or on behalf of IDT.

It is not intended that this presentation be relied upon and the information in this presentation does not take into account your financial objectives, situations or needs. Investors should consult with their own legal, tax, business and/or financial advisers in connection with any investment decision.

All numbers are as at 30 June 2021 unless otherwise stated. Numbers may not add up due to rounding.

All data presented in this document reflects the current views of the Company with respect to future events. Forward-looking statements are subject to a variety of risks, uncertainties and assumptions relating to the operations, results of operations, growth strategy and liquidity of the Company. Forward looking statements are also subject to external matters outside the control of the Company.

The release of this presentation has been authorised by IDT's Board of Directors.